Acta Virologica Vol.58, No.4, p.301-308, 2014

Quarterly,
Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Impact Factor = 1.82

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.58, No.4, p.301-308, 2014
Title: Targeting microRNA-122: Walking on cutting edge of hepatitis C virus infection therapy
Author: M. MOTAVAF, S. SAFARI, S. M. ALAVIAN

Abstract: Hepatitis C virus (HCV) infection, with an estimated 170 million carriers worldwide, remains a major cause of chronic liver disease. Current anti-HCV treatments have significant side effects and have met with only partial success. Therefore, a more effective therapeutic modality for HCV infection is needed. The stability and propagation of HCV is dependent on the interaction between its genome and a highly abundant liver microRNA (miRNA), known as microRNA-122 (miR-122). As a conserved host factor that would not be expected to evolve resistance mutations, miR-122 makes an attractive antiviral target. In this review we will discuss how targeting miR-122, using antisense oligonucleotides (ASOs), can be a new anti-HCV treatment.

Keywords: hepatitis C virus; microRNA; locked nucleic acid therapy; microRNA-122; human

Year: 2014, Volume: 58, Issue: 4	Page From: 301, Page To: 308
doi:10.4149/av_2014_04_301
	download file

Aepress.sk